ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2020
Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 162 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Passive Immunity Trial for Our Nation (PassItOn)
A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIOR)
Immune Responses to COVID-19 (SARS-CoV-2 Related Infection); Isolation of Human Neutralizing Monoclonal Antibodies for Therapeutics and Vaccine Design Approaches: a Prospective Monocentric Trial With Collaborative Sample Collection.
Who cites it
162 citing papers in PubMed, 2 syntheses or guidelines pooled it, 287 citations in OpenAlex.
- Clinical presentations, laboratory and radiological findings, and treatments for 11,028 COVID-19 patients: a systematic review and meta-analysis.Scientific reports · 2020Pooled it
- Pooled it
- Selected strains of the Ganoderma lucidum complex from Finnish forests have excellent broadly acting antiviral properties.Scientific reports · 2025Article
- Influenza Epidemiology in Finland During and After the COVID-19 Pandemic: Surveillance Data Analysis (2019-2024).Influenza and other respiratory viruses · 2025Article
- Convalescent plasma therapy for COVID-19 - Donor selection strategies and establishment of a plasma bank.New microbes and new infections · 2024Article
- Performance assessment of a new serological diagnostic test for COVID-19 with candidate peptides from spike and nucleocapsid viral proteins.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Clinical characteristics and outcomes of maintenance hemodialysis patients with COVID-19 during the Omicron wave of the pandemic in Beijing: a single center retrospective study.BMC nephrology · 2024Article
- Article
- Antiviral action of a functionalized plastic surface against human coronaviruses.Microbiology spectrum · 2024Article
- Article
- Article
- Long COVID-associated symptoms prevalent in both SARS-CoV-2 positive and negative individuals: A prospective follow-up study.New microbes and new infections · 2024Article
- Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector.Emerging microbes & infections · 2023Article
- Image-based and machine learning-guided multiplexed serology test for SARS-CoV-2.Cell reports methods · 2023Article
- The European experience with testing and surveillance during the first phase of the COVID-19 pandemic.Globalization and health · 2023Article
- Superspreading of SARS-CoV-2 Omicron BA.2.23 among vaccinated Finnish adults: symptomatic COVID-19 only contracted by those without recent infection.Epidemiology and infection · 2023Article
- Article
- Stable Levels of Antibodies Against Unrelated Toxoid Vaccines After COVID-19: COVID-19 Infection Does Not Affect Toxoid Vaccine Antibody Levels.Pathogens & immunity · 2023Article
- Antiviral functionalization of cellulose using tannic acid and tannin-rich extracts.Frontiers in microbiology · 2023Article
- Willow (Frontiers in microbiology · 2023Article
102 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first case of coronavirus disease (COVID-19) in Finland was confirmed on 29 January 2020. No secondary cases were detected. We describe the clinical picture and laboratory findings 3-23 days since the first symptoms. The SARS-CoV-2/Finland/1/2020 virus strain was isolated, the genome showing a single nucleotide substitution to the reference strain from Wuhan. Neutralising antibody response appeared within 9 days along with specific IgM and IgG response, targeting particularly nucleocapsid and spike proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.